High- or low-dose preoperative ipilimumab plus nivolumab in stage III urothelial cancer: the phase 1B NABUCCO trial.

Humans Nivolumab / adverse effects Ipilimumab / adverse effects Antineoplastic Combined Chemotherapy Protocols / adverse effects Neoplasms / chemically induced Progression-Free Survival

Journal

Nature medicine

ISSN: 1546-170X

Titre abrégé: Nat Med

Pays: United States

ID NLM: 9502015

Informations de publication

Date de publication:
03 2023

Historique:

received: 05 07 2022

accepted: 22 12 2022

pubmed: 3 2 2023

medline: 25 3 2023

entrez: 2 2 2023

Statut: ppublish

Résumé

Cohort 1 of the phase 1B NABUCCO trial showed high pathological complete response (pCR) rates with preoperative ipilimumab plus nivolumab in stage III urothelial cancer (UC). In cohort 2, the aim was dose adjustment to optimize responses. Additionally, we report secondary endpoints, including efficacy and tolerability, in cohort 2 and the association of presurgical absence of circulating tumor DNA (ctDNA) in urine and plasma with clinical outcome in both cohorts. Thirty patients received two cycles of either ipilimumab 3 mg kg

Identifiants

DOI: 10.1038/s41591-022-02199-y PMID: 36732628

pubmed: 36732628

doi: 10.1038/s41591-022-02199-y

pii: 10.1038/s41591-022-02199-y

doi:

Substances chimiques

Nivolumab 31YO63LBSN

Ipilimumab 0

Banques de données

ClinicalTrials.gov

['NCT03387761']

Types de publication

Clinical Trial, Phase I Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

Pagination

588-592

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Références

Witjes, J. A. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur. Urol. 79, 82–104 (2021).

doi: 10.1016/j.eururo.2020.03.055 pubmed: 32360052

Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur. Urol. 48, 202–205; discussion 205–206 (2005).

doi: 10.1016/j.eururo.2005.04.006

Pfister, C. et al. Randomized phase III trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin, or gemcitabine and cisplatin as perioperative chemotherapy for patients with muscle-invasive bladder cancer. Analysis of the GETUG/AFU V05 VESPER trial secondary endpoints: chemotherapy toxicity and pathological responses. Eur. Urol. 79, 214–221 (2021).

doi: 10.1016/j.eururo.2020.08.024 pubmed: 32868138

van Dijk, N. et al. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat. Med. 26, 1839–1844 (2020).

doi: 10.1038/s41591-020-1085-z pubmed: 33046870

Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948–960 (2019).

doi: 10.1016/S1470-2045(19)30151-2 pubmed: 31160251

Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566–576 (2020).

doi: 10.1038/s41591-020-0805-8 pubmed: 32251400

Vos, J. L. et al. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma. Nat. Commun. 12, 7348 (2021).

doi: 10.1038/s41467-021-26472-9 pubmed: 34937871 pmcid: 8695578

Rosenblatt, R. et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur. Urol. 61, 1229–1238 (2012).

doi: 10.1016/j.eururo.2011.12.010 pubmed: 22189383

Stimson, C. J. et al. Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J. Urol. 184, 1296–1300 (2010).

doi: 10.1016/j.juro.2010.06.007 pubmed: 20723939

Becker, R. E. N. et al. Clinical restaging and tumor sequencing are inaccurate indicators of response to neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 79, 364–371 (2021).

doi: 10.1016/j.eururo.2020.07.016 pubmed: 32814637

Powles, T. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595, 432–437 (2021).

doi: 10.1038/s41586-021-03642-9 pubmed: 34135506

Szabados, B. et al. Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder. Eur. Urol. 82, 212–222 (2022).

doi: 10.1016/j.eururo.2022.04.013 pubmed: 35577646

Flach, S. et al. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)—a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma. Br. J. Cancer 126, 1186–1195 (2022).

doi: 10.1038/s41416-022-01716-7 pubmed: 35132238 pmcid: 9023460

Sharma, P. et al. Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results. J. Clin. Oncol. 37, 1608–1616 (2019).

doi: 10.1200/JCO.19.00538 pubmed: 31100038 pmcid: 6879315

Plagnol, V. et al. Analytical validation of a next generation sequencing liquid biopsy assay for high sensitivity broad molecular profiling. PLoS ONE 13, e0193802 (2018).

doi: 10.1371/journal.pone.0193802 pubmed: 29543828 pmcid: 5854321

Gale, D. et al. Development of a highly sensitive liquid biopsy platform to detect clinically-relevant cancer mutations at low allele fractions in cell-free DNA. PLoS ONE 13, e0194630 (2018).

doi: 10.1371/journal.pone.0194630 pubmed: 29547634 pmcid: 5856404